We offer recombinant antibody production services for industrial applications or discovery research. Our focus is on recombinant antibody expression using in vitro CHO cell cultures.
A cooperation with us in recombinant antibody expression promises a fast project processing according to the highest quality standards.
We desire to meet tough deadlines and high quality requirements to recombinant antibody generation. This empowered us to built strong relationships with international pharmaceutical companies.
evitria is headquartered in Switzerland, but we have a worldwide customer base and a reputation as a leading CHO recombinant antibody expression specialist.
We are a service provider for recombinant antibody expression in CHO cells. We focus on this service only.
Therefore, we offer the highest standards in terms of quality and a fast processing.
For the generation of therapeutic antibodies with higher ADCC, we use the ProBioGen’s GlymaxX® technology, with which we have an exclusive licensing partnership. In addition, we can adapt our platform to transiently generate any secreted protein.
As a recombinant monoclonal antibody production company, we strive to offer you the best possible custom antibodies in the highest quality.
Therefore, we use CHO cells to express our recombinant monoclonal antibodies, easily surpassing functionality and reliability of competing polyclonal Abs and traditional hybridoma-derived monoclonal antibody products.
We are able to offer large-scale recombinant antibody production, either with or without afucosylation. Moreover, antibody production in CHO cell culture is much faster than any traditional technique. We are up to months faster than antibody suppliers relying on hybridoma cells.
Recombinant antibodies are antibodies and antibody fragments that are produced by using recombinant technology. They are Y-shaped proteins developed from immunoglobulins that constitute an integral part of the immune system in vertebrates.
As such, they are high-affinity binders to toxins and pathogens (antigens), showing very high specificities.Recombinant antibodies are expressed using optimized recombinant antibody coding genes.
This technology enables us to circumvent the usual drawbacks of traditional techniques, such as batch-to-batch variability, susceptibility to contaminations and allows the production of antibodies against toxins. Recombinant antibodies are famous for high specificity, outstanding quality and best yields.
Read more about recombinant antibodies: “Recombinant antibody – everything you need to know!”
ADCC (antibody-dependent cytotoxicity) is a mechanism of the immune system to fight infected and tumorigenic cells. Therapeutic antibodies with an artificially lowered fucose-content show enhanced ADCC activity and therefore increased potency and reduction in side-effects.
Since CHO cells are mammalian cell lines, their antibodies are posttranslationally modified with oligosaccarides. Many modern Ab applications call for intact glycosylation patterns and our mammalian cell lines take care of this requirement.
Antibodies lacking fucose are termed afucosylated antibodies and were found to be promising drug candidates and research tools due to enhancement of ADCC.
The impact of those glycosylation modifications is the subject of numerous research projects in pharmaceutical companies and academic institutions.
By virtue of our exclusive licensing partnership, we offer afucosylation via ProBioGen’s GlymaxX® technology to our customers.
ADCC enhanced antibodies
Afucosylated antibodies share the characteristics of recombinant antibodies, i.e. very high specificity for an antigen. Additionally they show a decreased content or lack of fucose.
This triggers the immune system to produce a ferocious response to the antigen (ADCC). Therefore, afucosylated antibodies hold great promise in the development of therapies against cancer and infections.
Read more about ADCC enhanced antibodies: “ADCC antibody – The benefits of ADCC enhanced antibodies“
Your protein production needs to go beyond recombinant antibodies? The recombinant antibody expression platform at evitria is flexible. We can meet your needs for any secreted proteins (scFvs, soluble extracellular domains, cytokines, viral proteins and more).
We deliver nano-filtered, sterile supernatant for your established inhouse downstream processes. Get in touch with us to obtain more information.
Recombinant antibody production service supplied by evitria encompasses complete recombinant antibody expression for our customers.
Do you face any production capacity bottlenecks in the near future? For individual projects, evitria offers to solve customer’s capacity bottlenecks through contract production jobs.
In contrast, we also offer long term partnerships to manage any production capacity bottleneck, as well as complete antibody productions for our customers. Our partners benefit from our expertise, quality and speed in outsourcing their recombinant antibody production.
Our customers value our wealth of expertise in the transient antibody expression in CHO cells that we accumulated since evitria’s inception in 2010.
We stand above our competition in production timelines: we begin new projects within one day and often complete orders with record setting completion times.
Our customers consider reliability to be of paramount importance. Our focus and expertise enable us to deliver on our promises of product quality, material quantity and delivery timelines.
We at evitria have a track record of over 60.000 transfections and delivered more than 10.000 antibodies to international customers.
We have accumulated a wealth of experience and offer our expertise to serve our customers as a contract research organization, in short CRO, for recombinant antibody expression.
Our recombinant antibody expression platform leverages the advantages of CHO cells. Our processes are independent of laboratory animals and their immunization, therefore our recombinant antibodies are free of animal contaminations.
Our CHO based expression platform enables us to guarantee shorter timelines and higher yields than possible with traditional, out-dated methods.
We are up to months faster than competitors. We commence projects within one day of customer’s approval and complete a pilot study within 15 – 20 days. The subsequent on-scale expression takes 5 – 10 days and the product isolation is typically finished after 2 – 3 days.
Next, the final analytics are completed within 2 – 3 days. To conclude, we hand over the products to our logistics partner and have them delivered to you in 1 – 2 business days. Our typical project timeline from start to finish is five weeks.
We are looking forward to receiving your orders and are happy to answer any questions! Get in contact with us via the contact form. We will get back to you within 24 hours.
No, we use mammalian cell cultures. We prefer Chinese Hamster Ovarian (CHO) cells in our mammalian expression system, since that comes with numerous advantages over the use of laboratory animals.
Mammalian expression is the process of biological protein production in mammals or mammalian cells. Some proteins, such as antibodies, can’t be produced in fully functional form in other cell cultures.
No, at this time we can’t offer high throughput screening of antibodies.
A recombinant gene is a sequence of genetic code that is inserted into different genetic material by biotechnological techniques. Recombinant genes are used to transfer blueprints of proteins (e. g. recombinant antibodies) into cells in order to have them produce said protein.
evitria offers custom antibodies to their customers. Our service includes recombinant antibodies, afucosylated antibodies or other proteins. In contrast to a conventional antibody supplier, we do not offer a catalog with standardized antibodies.
Antibody engineering is the process of changing and optimizing antibodies to equip them with better or novel properties. One example is the fine-tuning of antigen binding sites to enhance affinity or specificity towards an antigen.
Another example is the fusion of two antibodies with distinct antigens, to form a bispecific antibody that shows affinity towards both antigens.